Oxidized Lipids in Human Diseases

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Aberrant Oxidation of Biomolecules".

Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 2175

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA
Interests: lipid metabolism; inflammation; signal transduction; neurodegenerative disease; mitochondria; macrophage/microglia biology

Special Issue Information

Dear Colleagues,

Oxidation of low-density lipoprotein (LDL) is considered a major risk factor for cardiovascular disease (CVD). Accumulating evidence shows that oxidized lipids and their active components, e.g., oxidized cholesteryl esters (OxCEs), implicate chronic inflammatory diseases, such as atherosclerosis. In the context of atherosclerosis, oxidized lipids are host-derived damaged-associated molecular patterns (DAMPs) which arise during the progression of atherosclerosis, and their accumulation has been found in human lesions as well as hypercholesterolemic animal models (mouse and zebrafish). However, the features of oxidized LDL and the underlying mechanisms in human diseases are still not clearly understood.

Thus, this Special Issue of Antioxidants will encourage researchers to publish your latest research papers and review articles on aspects of the role of oxidized lipids in human diseases. This research will be able to include both in vivo and in vitro studies relating to any of various concepts regarding oxidized lipids and human diseases, such as atherosclerosis and inflammatory disease. Your contribution will help toward a better understanding of the mechanism by which oxidized lipids induce human diseases and to generate the new treatments of oxidized lipid-related human diseases.

We look forward to your contribution.

Dr. Soo-Ho Choi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Oxidized lipids 
  • Oxidized cholesteryl esters (OxCEs) 
  • Oxidized low-density lipoprotein (OxLDL) 
  • Lipoproteins 
  • Inflammatory diseases 
  • Damaged-associated molecular patterns (DAMPs)

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 6061 KiB  
Article
Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease
by Kouichi Miura, Naoshi Arai, Rie Goka, Naoki Morimoto, Shunji Watanabe, Norio Isoda, Hironori Yamamoto and Kazuhiko Kotani
Antioxidants 2021, 10(2), 239; https://doi.org/10.3390/antiox10020239 - 4 Feb 2021
Cited by 4 | Viewed by 1824
Abstract
Patients with nonalcoholic fatty liver disease (NAFLD) show dyslipidemia and a high risk for coronary heart disease (CHD). However, conventional atherosclerotic lipids are found at low levels in NAFLD patients with advanced fibrosis, in whom the risk for CHD is extremely high. The [...] Read more.
Patients with nonalcoholic fatty liver disease (NAFLD) show dyslipidemia and a high risk for coronary heart disease (CHD). However, conventional atherosclerotic lipids are found at low levels in NAFLD patients with advanced fibrosis, in whom the risk for CHD is extremely high. The aim of the present study was to evaluate the levels of oxidized high-density lipoprotein (oxHDL), an emerging atherosclerotic biomarker, in patients with NAFLD. A total of 32 non-NAFLD subjects and 106 patients with NAFLD were enrolled. The fibrosis grades were stratified using non-invasive methods, including the Fibrosis-4 index and NAFLD fibrosis score. Total cholesterol and low-density lipoprotein (LDL)-cholesterol levels were significantly low in patients with advanced liver fibrosis. In contrast, oxHDL levels were high in NAFLD patients and showed a stepwise increase as fibrosis progressed. These oxHDL levels were independent of the HDL cholesterol levels, and statin use did not influence the oxHDL levels. Obese patients showed no increase in oxHDL levels, whereas patients with a low handgrip strength showed high oxHDL levels in NAFLD with advanced fibrosis. In conclusion, oxHDL is a potential biomarker for assessing the status of patients with NAFLD, including CHD and metabolic/nutritional disturbance, and particular cases with advanced liver fibrosis. Full article
(This article belongs to the Special Issue Oxidized Lipids in Human Diseases)
Show Figures

Figure 1

Back to TopTop